<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="ctm270341" xml:lang="en" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2001-1326</journal-id><journal-id journal-id-type="publisher-id">CTM2</journal-id><journal-title-group><journal-title>Clinical and Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">2001-1326</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40405488</article-id><article-id pub-id-type="pmc">PMC12098955</article-id><article-id pub-id-type="doi">10.1002/ctm2.70341</article-id><article-id pub-id-type="publisher-id">CTM270341</article-id><article-categories><subj-group subj-group-type="overline"><subject>Letter to the Journal</subject></subj-group><subj-group subj-group-type="heading"><subject>Letter to the Journal</subject></subj-group></article-categories><title-group><article-title>Macrophage C1q contributes to pulmonary fibrosis by disturbing the metabolism of alveolar epithelial cells</article-title><alt-title alt-title-type="left-running-head">PR&#x000dc;FER <sc>et&#x000a0;al.</sc>
</alt-title></title-group><contrib-group><contrib id="ctm270341-cr-0001" contrib-type="author"><name><surname>Pr&#x000fc;fer</surname><given-names>Fenja</given-names></name><xref rid="ctm270341-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ctm270341-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ctm270341-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ctm270341-cr-0002" contrib-type="author"><name><surname>Steer</surname><given-names>Beatrix</given-names></name><xref rid="ctm270341-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="ctm270341-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ctm270341-cr-0003" contrib-type="author"><name><surname>Kaufmann</surname><given-names>Eva</given-names></name><xref rid="ctm270341-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ctm270341-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ctm270341-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ctm270341-cr-0004" contrib-type="author"><name><surname>Wolf</surname><given-names>Peter</given-names></name><xref rid="ctm270341-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="ctm270341-cr-0005" contrib-type="author"><name><surname>Adler</surname><given-names>Barbara</given-names></name><xref rid="ctm270341-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="ctm270341-cr-0006" contrib-type="author"><name><surname>Korfei</surname><given-names>Martina</given-names></name><xref rid="ctm270341-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="ctm270341-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="ctm270341-cr-0007" contrib-type="author"><name><surname>G&#x000fc;nther</surname><given-names>Andreas</given-names></name><xref rid="ctm270341-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="ctm270341-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="ctm270341-cr-0008" contrib-type="author"><name><surname>K&#x000f6;nigshoff</surname><given-names>Melanie</given-names></name><xref rid="ctm270341-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="ctm270341-cr-0009" contrib-type="author" corresp="yes"><name><surname>Adler</surname><given-names>Heiko</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6481-6709</contrib-id><xref rid="ctm270341-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ctm270341-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="ctm270341-aff-0010" ref-type="aff">
<sup>10</sup>
</xref><address><email>heiko.adler@lrz.uni-muenchen.de</email></address></contrib></contrib-group><aff id="ctm270341-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Comprehensive Pneumology Center, Research Unit Lung Repair and Regeneration, Helmholtz Zentrum M&#x000fc;nchen &#x02010; German Research Center for Environmental Health</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="ctm270341-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">University Hospital Grosshadern</named-content>
<institution>Ludwig&#x02010;Maximilians&#x02010;University Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="ctm270341-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>German Center for Lung Research (DZL/CPC&#x02010;M)</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="ctm270341-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Institute of Asthma and Allergy Prevention, Helmholtz Zentrum M&#x000fc;nchen, German Research Center for Environmental Health</institution>
<city>Neuherberg</city>
<country country="DE">Germany</country>
</aff><aff id="ctm270341-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>INCYTON GmbH</institution>
<city>Planegg</city>
<country country="DE">Germany</country>
</aff><aff id="ctm270341-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Max von Pettenkofer Institute &#x00026; Gene Center, Virology, Faculty of Medicine</named-content>
<institution>Ludwig&#x02010; Maximilians&#x02010;University Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="ctm270341-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Justus&#x02010;Liebig&#x02010;University Giessen</institution>
<city>Giessen</city>
<country country="DE">Germany</country>
</aff><aff id="ctm270341-aff-0008">
<label>
<sup>8</sup>
</label>
<institution>German Center for Lung Research (DZL), Universities of Giessen and Marburg Lung Center (UGMLC)</institution>
<city>Giessen</city>
<country country="DE">Germany</country>
</aff><aff id="ctm270341-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>University of Pittsburgh</institution>
<city>Pittsburgh</city>
<named-content content-type="country-part">Pennsylvania</named-content>
<country country="US">USA</country>
</aff><aff id="ctm270341-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Walther Straub Institute of Pharmacology and Toxicology</named-content>
<institution>Ludwig&#x02010;Maximilians&#x02010;University Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Heiko Adler, Walther Straub Institute of Pharmacology and Toxicology, Munich, Germany.<break/> Email: <email>heiko.adler@lrz.uni-muenchen.de</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>15</volume><issue seq="240">5</issue><issue-id pub-id-type="doi">10.1002/ctm2.v15.5</issue-id><elocation-id>e70341</elocation-id><history>
<date date-type="rev-recd"><day>28</day><month>4</month><year>2025</year></date>
<date date-type="received"><day>20</day><month>3</month><year>2025</year></date>
<date date-type="accepted"><day>13</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Clinical and Translational Medicine</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CTM2-15-e70341.pdf"/><funding-group><award-group id="funding-0001"><funding-source>F&#x000f6;FoLe&#x02010;program of the LMU Munich</funding-source></award-group><award-group id="funding-0002"><funding-source>German Center for Lung Research (DZL)</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="0"/><page-count count="5"/><word-count count="2405"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:23.05.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="opening-section" id="ctm270341-sec-0010"><label>1</label><p>Dear Editor,</p><p>Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease, driven primarily by damage and dysfunction of type&#x02010;II alveolar epithelial cells (AECII). Since there is still no cure for IPF, new therapeutic approaches are desirable. In this study, we identified the complement component C1q as a source of disturbance of AECII metabolism.</p><p>When analyzing publicly available data,<xref rid="ctm270341-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> we found that C1q mRNA expression is upregulated in IPF patients (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S1</xref>). Therefore, we analyzed bronchoalveolar lavage fluids (BALF) of IPF patients for the presence of C1qA. Compared to controls, significantly increased levels of C1qA were present in BALF of IPF patients (Figure&#x000a0;<xref rid="ctm270341-fig-0001" ref-type="fig">1A</xref>). To investigate the role of C1q in fibrosis development, we used a virus&#x02010;induced mouse model of IPF.<xref rid="ctm270341-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> First, we determined C1qA gene expression in lungs of both control (wild&#x02010;type) and fibrosis&#x02010;prone (interferon [IFN]&#x02010;&#x003b3;R&#x02010;/&#x02010;) mice, analyzing uninfected mice and mice 14 days (acute inflammation phase), around 45 days (early fibrosis phase), and around 100 days (fibrosis phase) after infection with murine gammaherpesvirus 68 (MHV&#x02010;68). C1qA was highly expressed in the acute inflammation phase in both mouse strains. It subsequently declined over time in wild&#x02010;type mice whereas the decline was much less pronounced in IFN&#x02010;&#x003b3;R&#x02010;/&#x02010; mice (Figure&#x000a0;<xref rid="ctm270341-fig-0001" ref-type="fig">1B</xref>). No differences were observed when comparing whole lung tissue protein levels (Figure&#x000a0;<xref rid="ctm270341-fig-0001" ref-type="fig">1C</xref>). However, mice with lung fibrosis (IFN&#x02010;&#x003b3;R&#x02010;/&#x02010;) showed significantly elevated C1qA protein in BALF (Figure&#x000a0;<xref rid="ctm270341-fig-0001" ref-type="fig">1D</xref>). This was due to local production and secretion as in mice with increased C1qA in BALF (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S2A</xref>), C1qA in serum remained constant (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S2B</xref>). Higher C1qA gene expression in fibrotic mice was also observed in other fibrosis mouse models when analyzing publicly available data (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S3</xref>).</p><fig position="float" fig-type="FIGURE" id="ctm270341-fig-0001"><label>FIGURE 1</label><caption><p>Increased levels of C1QA in BAL fluids of both IPF patients and fibrotic mice. (A) C1QA in BAL fluids of IPF patients was determined by ELISA. The data are presented as violin plots, with median and quartiles indicated. Each symbol represents one individual (Donor: <italic toggle="yes">n =</italic>&#x000a0;14; IPF: <italic toggle="yes">n =</italic>&#x000a0;10). The asterisk indicates a statistically significant difference (Mann&#x02010;Whitney test). (B) Lungs of uninfected (<italic toggle="yes">n =</italic>&#x000a0;6 per group) and MHV&#x02010;68 infected C57BL/6 (WT) and IFN&#x02010;&#x003b3; R&#x02010;/&#x02010; (KO) mice were harvested during acute inflammation (<italic toggle="yes">n =</italic>&#x000a0;5 per group), early fibrosis (<italic toggle="yes">n =</italic>&#x000a0;5 per group) and fibrosis (<italic toggle="yes">n =</italic>&#x000a0;3&#x02010;5 per group). RNA was isolated from the tissue and C1qA expression was analyzed by qRT&#x02010;PCR, normalized to &#x003b2;&#x02010;actin (Actb), and displayed relative to Actb. Results are shown as Box&#x02010;Whisker&#x02010;Plots, and each symbol represents an individual mouse. ns: not significant (One&#x02010;way ANOVA). (C) Lungs of uninfected and MHV&#x02010;68 infected C57BL/6 (WT; <italic toggle="yes">n =</italic>&#x000a0;3) and IFN&#x02010;&#x003b3; R&#x02010;/&#x02010; (KO; <italic toggle="yes">n =</italic>&#x000a0;3) mice were harvested during acute inflammation, early fibrosis and fibrosis. C1QA and &#x003b2;&#x02010;actin (ACTB) protein levels were analyzed by Western blot (upper panel). Band density was measured with ImageJ, adjusted to &#x003b2;&#x02010;actin levels, and displayed as adjusted density (lower panel). Each symbol represents an individual mouse, and the columns represent the mean&#x000a0;&#x000b1;&#x000a0;SD. ns: not significant (Kruskal&#x02010;Wallis test). (D) BAL fluids of uninfected (<italic toggle="yes">n =</italic>&#x000a0;3 per group) and MHV&#x02010;68 infected C57BL/6 (WT) and IFN&#x02010;&#x003b3; R&#x02010;/&#x02010; (KO) mice were collected during acute inflammation (<italic toggle="yes">n =</italic>&#x000a0;5 per group), early fibrosis (<italic toggle="yes">n =</italic>&#x000a0;5&#x02010;6 per group) and fibrosis (<italic toggle="yes">n =</italic>&#x000a0;6 per group). C1QA concentration was measured by ELISA. Results are shown as Box&#x02010;Whisker&#x02010;Plots, and each symbol represents an individual mouse. The asterisks indicate a statistically significant difference (One&#x02010;way ANOVA).</p></caption><graphic xlink:href="CTM2-15-e70341-g003" position="anchor" id="jats-graphic-1"/></fig><p>To determine the cellular source of C1q in the lung, we analyzed C1q gene expression in publicly available single&#x02010;cell RNA sequencing data (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S4</xref>). In human lungs, macrophages are the main producers of C1qA, C1qB and C1qC. We immuno&#x02010;stained sequential slices of murine lungs with the macrophage marker F4/80 and anti&#x02010;C1qA (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S5A</xref>), and sequential slices of human lungs with anti&#x02010;C1qA, the macrophage marker CD68 and the AECII marker proSPC (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S5B</xref>). In both cases, macrophages stained positive for C1qA. To further analyze C1q production by macrophages, we polarized MH&#x02010;S cells (a murine alveolar macrophage cell line) into either M1 or M2 macrophages. Treatment with LPS + IFN&#x02010;&#x003b3; led to an increase in Nos2 expression, an M1 marker, while treatment with IL&#x02010;4 resulted in increased Arg1 expression, an M2 marker (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S6A</xref>). Polarization into M2 macrophages did not increase cell&#x02010;associated C1qA (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S6B</xref>) but significantly increased C1qA in the supernatant (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S6C</xref>).</p><p>We hypothesized that secreted C1qA might affect other cells in a paracrine fashion and focused on AECII. MLE&#x02010;12 cells, a well&#x02010;established murine AECII line, were treated with native human C1q that also reacts with murine cells.<xref rid="ctm270341-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> We observed a dose&#x02010;dependent reduction in MTT (3&#x02010;(4,5&#x02010;dimethylthazolk&#x02010;2&#x02010;yl)&#x02010;2,5&#x02010;diphenyltetrazolium bromide)&#x02010;assay activity (Figure&#x000a0;<xref rid="ctm270341-fig-0002" ref-type="fig">2A</xref>), suggesting that C1q induces cell death of AECII since the MTT&#x02010;assay is commonly used as a measure of cell viability.<xref rid="ctm270341-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Since we did not observe a corresponding increase of lactate dehydrogenase (LDH)&#x02010;activity (an indicator of necrosis) in the supernatants of the treated cells (Figure&#x000a0;<xref rid="ctm270341-fig-0002" ref-type="fig">2B</xref>), we speculated that C1q induces non&#x02010;necrotic cell death of AECII. As apoptosis of AECII is a main characteristic of IPF, we conducted an Apoptosis and Necrosis Assay. C1q did neither induce apoptosis (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S7A</xref>) nor necrosis (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S7B</xref>). We further confirmed the absence of apoptosis by both the Caspase&#x02010;Glo 3/7 Assay (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S7C</xref>) and Western blot for cleaved PARP (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S7D</xref>). Next, we analyzed other known cell death pathways including ferroptosis, autophagy&#x02010;dependent cell death, necroptosis, pyroptosis and parthanatos. We treated MLE&#x02010;12 cells with C1q in the presence or absence of specific cell death inhibitors, and subsequently determined cell viability by MTT&#x02010;assay, a strategy successfully applied by others.<xref rid="ctm270341-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="ctm270341-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> None of the inhibitors was able to reverse the C1q&#x02010;induced reduction in MTT&#x02010;assay activity (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S8</xref>). To support these findings, we determined the gene expression of characteristic cell death&#x02010;associated genes including Bax, Bcl&#x02010;xl, Acsl4, RIPK3 and NLRP3 (Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S9</xref>). We did not observe significant differences between control&#x02010; or C1q&#x02010;treated MLE&#x02010;12 cells.</p><fig position="float" fig-type="FIGURE" id="ctm270341-fig-0002"><label>FIGURE 2</label><caption><p>C1QA induces metabolic decline of AECII. (A) MLE&#x02010;12 cells were treated with C1q in concentrations ranging from 100&#x000a0;&#x000b5;g/mL to 0.4&#x000a0;&#x000b5;g/mL in a 3&#x02010;fold dilution series. Culture medium served as control. Metabolic activity was measured 48&#x000a0;h after treatment with an MTT assay. Values were normalized to the mean of the control group and are presented as a fraction of the control. Each symbol represents an individual experiment, and the columns represent the mean&#x000a0;&#x000b1;&#x000a0;SD. The asterisks indicate a statistically significant difference (One&#x02010;way ANOVA). (B) MLE&#x02010;12 cells were treated with different concentrations of C1q. Culture medium and Triton X 100 served as negative and positive controls. Cytotoxicity was measured 48&#x000a0;h after treatment by measuring LDH concentration with an LDH assay. Values were normalized to the mean of the control group and are presented as a fraction of control. Each symbol represents an individual experiment, and the columns represent the mean&#x000a0;&#x000b1;&#x000a0;SD. ns: not significant. (C&#x02013;E) MLE&#x02010;12 cells were pre&#x02010;measured (baseline) for 24&#x000a0;h and then treated with C1q (33&#x000a0;&#x000b5;g/mL) or with diluent (medium) as a control as indicated. Metabolic rates (OCR [panel C] and ECAR [panel D]) were determined during the next 48&#x000a0;h. The data shown are the means and standard deviations of 3&#x02013;4 replicates. Microscopic images of all wells were taken periodically throughout the entire experiment, and exemplary images from the indicated time points are shown in panel E.</p></caption><graphic xlink:href="CTM2-15-e70341-g001" position="anchor" id="jats-graphic-3"/></fig><p>Since our data suggested that the reduction in formazan formation (MTT&#x02010;assay) upon C1q treatment is not due to AECII death, we performed multiparametric monitoring of cellular metabolic responses, continuously measuring oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) and simultaneously performing periodic microscopic imaging using the CYRIS FLOX analysis platform (INCYTON GmbH, Planegg, Germany). Treatment of MLE&#x02010;12 cells with a moderate dose of C1q (33&#x000a0;&#x000b5;g/mL) resulted in a significant reduction of both OCR (Figure&#x000a0;<xref rid="ctm270341-fig-0002" ref-type="fig">2C</xref>) and ECAR (Figure&#x000a0;<xref rid="ctm270341-fig-0002" ref-type="fig">2D</xref>) (C1q vs. control: <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05; Mann&#x02010;Whitney test). In contrast, the morphological integrity of the cells was not affected (Figure&#x000a0;<xref rid="ctm270341-fig-0002" ref-type="fig">2E</xref>).</p><p>Finally, we applied a C1q inhibitory peptide<xref rid="ctm270341-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> that has already been successfully used in vivo in a mouse model of chronic hepatitis<xref rid="ctm270341-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> to investigate fibrosis development in the presence or absence of the peptide. IFN&#x02010;&#x003b3;R&#x02010;/&#x02010; mice were left uninfected or were infected with MHV&#x02010;68. From day 44 (=&#x000a0;early fibrosis phase) after infection, the infected mice were either treated i.p. with 2J peptide (2&#x000a0;mg/kg) or with vehicle control twice a week as described by others<xref rid="ctm270341-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> until day 85 (=&#x000a0;fibrotic phase) after infection. Treatment with the C1q inhibitory peptide significantly improved peripheral oxygen saturation (SpO<sub>2</sub>) (Figure&#x000a0;<xref rid="ctm270341-fig-0003" ref-type="fig">3A</xref>), and considerably prevented fibrosis development as determined by Hematoxylin/Eosin&#x02010; and Masson&#x02010;Goldner trichrome&#x02010;staining of lung sections (Figure&#x000a0;<xref rid="ctm270341-fig-0003" ref-type="fig">3B,C</xref>; Figure <xref rid="ctm270341-supinfo-0001" ref-type="">S10</xref>) and by measurement of mean septal thickness (an indicator of fibrosis) (Figure&#x000a0;<xref rid="ctm270341-fig-0003" ref-type="fig">3D</xref>).</p><fig position="float" fig-type="FIGURE" id="ctm270341-fig-0003"><label>FIGURE 3</label><caption><p>Inhibition of C1q in vivo reduces fibrosis development. IFN&#x02010;&#x003b3; R&#x02212;/&#x02212; (KO) mice were left uninfected (<italic toggle="yes">n =</italic>&#x000a0;2) or were infected with MHV&#x02010;68 (<italic toggle="yes">n =</italic>&#x000a0;8). Beginning at day 44 (=&#x000a0;early fibrosis phase) after infection, the infected mice were either treated i.p. with 2J peptide (2&#x000a0;mg/kg) (<italic toggle="yes">n =</italic>&#x000a0;4) or with vehicle control (<italic toggle="yes">n =</italic>&#x000a0;4) twice a week. (A) SpO<sub>2</sub> was determined at the indicated time points using a Pulse Oximeter for mice (MSTAT&#x02010;JR, Kent Scientific Corporation). Data shown are means&#x000a0;&#x000b1;&#x000a0;SD. The asterisks indicate a statistically significant difference (unpaired, two&#x02010;sided t&#x02010;test). ns: not significant. (B) At day 85 after infection (=&#x000a0;fibrosis phase), all mice were sacrificed, and the lungs were prepared for histology. Representative Hematoxylin/Eosin (HE)&#x02010; and Masson&#x02010;Goldner (MG) trichrome&#x02010;stained sections are shown. Scale bars indicate either 1&#x000a0;mm or 2.5&#x000a0;mm. (C) Densitometric quantification of sections from left and right lungs using ImageJ. (D) Measurement of the length of mean septal thickness (&#x000b5;m) in HE&#x02010;stained lung sections from left and right lungs. This measurement was performed by a researcher blinded to the study groups. In panels (C) and (D), each symbol represents the value of an individual lung section, and the columns represent the mean&#x000a0;&#x000b1;&#x000a0;SD. The asterisk indicates a statistically significant difference (Kruskal&#x02010;Wallis test).</p></caption><graphic xlink:href="CTM2-15-e70341-g002" position="anchor" id="jats-graphic-5"/></fig><p>In summary, we identified C1q, produced by macrophages, as an inducer of a metabolic disorder of AECII, emphasizing the importance of macrophage&#x02014;epithelial cross&#x02010;talk for the development of pulmonary fibrosis, and propose C1q as a potential new therapeutic target.</p></sec><sec id="ctm270341-sec-0020"><title>AUTHOR CONTRIBUTIONS</title><p>Fenja Pr&#x000fc;fer performed experiments and analyzed and interpreted the data. Beatrix Steer performed experiments. Eva Kaufmann performed experiments and analyzed and interpreted the data. Peter Wolf performed experiments and analyzed and interpreted the data. Barbara Adler discussed and interpreted the data, and reviewed and revised the final manuscript. Martina Korfei performed experiments and analyzed and interpreted the data. Andreas G&#x000fc;nther discussed and interpreted the data. Melanie K&#x000f6;nigshoff discussed and interpreted the data. Heiko Adler supervised the project, designed the experiments, analyzed the data and wrote and edited the paper.</p></sec><sec sec-type="COI-statement" id="ctm270341-sec-0040"><title>CONFLICT OF INTEREST STATEMENT</title><p>Peter Wolf is an employee of the company INCYTON GmbH (Germany), which developed and distributes the utilized analysis platform CYRIS FLOX. All other authors declare no conflict of interest.</p></sec><sec id="ctm270341-sec-0050"><title>FUNDING INFORMATION</title><p>This work was funded by the F&#x000f6;FoLe&#x02010;program of the LMU Munich as well as by the German Center for Lung Research (DZL).</p></sec><sec id="ctm270341-sec-0080"><title>ETHICS STATEMENT</title><p>The study was approved by the local ethics committee of the Ludwig&#x02010;Maximilians&#x02010;University Munich, Germany (Projects 333&#x02010;10, 455&#x02010;12).</p></sec><sec id="ctm270341-sec-0090"><title>PATIENT CONSENT STATEMENT</title><p>Written informed consent was obtained for all study participants. The animal study protocol was approved by the government of Upper Bavaria and performed in compliance with the German Animal Welfare Act.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="ctm270341-supinfo-0001" position="float" content-type="local-data"/><supplementary-material id="ctm270341-supitem-0001" position="float" content-type="local-data"><caption><p>Supporting Information</p></caption><media xlink:href="CTM2-15-e70341-s001.docx"/></supplementary-material></sec></body><back><ack id="ctm270341-sec-0030"><title>ACKNOWLEDGEMENTS</title><p>We are grateful to the members of our animal facilities for expert technical assistance. We also thank the members of our groups for helpful discussions. We gratefully acknowledge the provision of human BAL and tissue samples and clinical data from the CPC&#x02010;M bioArchive and its partners at the Hospital of the Ludwig&#x02010;Maximilians&#x02010;University Munich, the Asklepios Biobank Gauting and the Ludwig&#x02010;Maximilians&#x02010;University Munich. We thank the patients and their families for their support.</p><p>Open access funding enabled and organized by Projekt DEAL.</p></ack><sec sec-type="data-availability" id="ctm270341-sec-0070"><title>DATA AVAILABILITY STATEMENT</title><p>The data presented in this study are available upon request from the corresponding author.</p></sec><ref-list id="ctm270341-bibl-0001"><title>REFERENCES</title><ref id="ctm270341-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ctm270341-cite-0002">
<string-name>
<surname>McDonough</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Ahangari</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Q</given-names>
</string-name>, et&#x000a0;al. <article-title>Transcriptional regulatory model of fibrosis progression in the human lung</article-title>. <source>JCI Insight</source>. <year>2019</year>;<volume>4</volume>:<elocation-id>e131597</elocation-id>.<pub-id pub-id-type="pmid">31600171</pub-id>
</mixed-citation></ref><ref id="ctm270341-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ctm270341-cite-0003">
<string-name>
<surname>Mora</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Woods</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Garcia</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Lung infection with gamma&#x02010;herpesvirus induces progressive pulmonary fibrosis in Th2&#x02010;biased mice</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. <year>2005</year>;<volume>289</volume>:<fpage>L711</fpage>&#x02010;<lpage>L721</lpage>.<pub-id pub-id-type="pmid">15734789</pub-id>
</mixed-citation></ref><ref id="ctm270341-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ctm270341-cite-0004">
<string-name>
<surname>Naito</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sumida</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nomura</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Complement C1q activates canonical Wnt signaling and promotes aging&#x02010;related phenotypes</article-title>. <source>Cell</source>. <year>2012</year>;<volume>149</volume>:<fpage>1298</fpage>&#x02010;<lpage>1313</lpage>.<pub-id pub-id-type="pmid">22682250</pub-id>
</mixed-citation></ref><ref id="ctm270341-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ctm270341-cite-0005">
<string-name>
<surname>Ghasemi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Turnbull</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sebastian</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kempson</surname>
<given-names>I</given-names>
</string-name>. <article-title>The MTT Assay: utility, limitations, pitfalls, and interpretation in bulk and single&#x02010;cell analysis</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>. doi:<pub-id pub-id-type="doi">10.3390/ijms222312827</pub-id>
</mixed-citation></ref><ref id="ctm270341-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ctm270341-cite-0006">
<string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Pfau</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ling</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nathan</surname>
<given-names>CF</given-names>
</string-name>. <article-title>Type I interferon signaling mediates <italic toggle="yes">Mycobacterium tuberculosis</italic>&#x02010;induced macrophage death</article-title>. <source>J Exp Med</source>. <year>2021</year>;<volume>218</volume>:<elocation-id>e20200887</elocation-id>.<pub-id pub-id-type="pmid">33125053</pub-id>
</mixed-citation></ref><ref id="ctm270341-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ctm270341-cite-0007">
<string-name>
<surname>Linder</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bauernfried</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>Y</given-names>
</string-name>, et&#x000a0;al. <article-title>CARD8 inflammasome activation triggers pyroptosis in human T cells</article-title>. <source>Embo j</source>. <year>2020</year>;<volume>39</volume>:<elocation-id>e105071</elocation-id>. doi:<pub-id pub-id-type="doi">10.15252/embj.2020105071</pub-id>
<pub-id pub-id-type="pmid">32840892</pub-id>
</mixed-citation></ref><ref id="ctm270341-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ctm270341-cite-0008">
<string-name>
<surname>Roos</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nauta</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Broers</surname>
<given-names>D</given-names>
</string-name>, et&#x000a0;al. <article-title>Specific inhibition of the classical complement pathway by C1q&#x02010;binding peptides</article-title>. <source>J Immunol</source>. <year>2001</year>;<volume>167</volume>:<fpage>7052</fpage>&#x02010;<lpage>7059</lpage>.<pub-id pub-id-type="pmid">11739526</pub-id>
</mixed-citation></ref><ref id="ctm270341-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ctm270341-cite-0009">
<string-name>
<surname>Ho</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Yeh</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Complement C1q mediates the expansion of periportal hepatic progenitor cells in senescence&#x02010;associated inflammatory liver</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2020</year>;<volume>117</volume>:<fpage>6717</fpage>&#x02010;<lpage>6725</lpage>.<pub-id pub-id-type="pmid">32139604</pub-id>
</mixed-citation></ref></ref-list></back></article>